Pharmacologic Approaches to Diabetes Management: Glucagon-Like Peptide-1 Based Therapies
Target Audience: Pharmacist, Pharmacy Tech, Physician Assistant, Physician
Course Overview
Diabetes mellitus remains a significant public health problem as a leading cause of death and micro- and macrovascular morbidity. The management of diabetes continues to evolve as new research, technology, and treatments allow for enhanced patient care. It is vital for health care providers, including physicians, nurses, and pharmacists, to be current with diabetes care guidelines, including the pharmacologic management of diabetes mellitus. This course will review glucagon-like peptide-1-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Dosing regimens, side effects, and monitoring parameters will be discussed. The role of GLP-1-based therapies within therapeutic regimens for patients with Type 2 diabetes mellitus will be discussed in the context of the updated American Diabetes Association Standards of Care in Diabetes 2023 guidelines.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Compare and contrast available glucagon-like peptide-1-based medications
- Identify side effects and contraindications of glucagon-like peptide-1-based medications
- Identify when to utilize glucagon-like peptide-1-based medications within a therapeutic regimen for patients with Type 2 diabetes
- Recall patient counseling points related to the use of glucagon-like peptide-1-based medications
Faculty
- Introduction
- Guidelines for Managing Diabetes and Comorbidities
- Exenatide (Byetta, Bydureon, Bydureon BCise)
- Liraglutide (Victoza)
- Insulin Degludec/Liraglutide (Xultophy 100/3.6)
- Dulaglutide (Trulicity)
- Lixisenatide (Adylxin)
- Insulin Glargine/Lixisenatide (Soliqua 100/33)
- Semaglutide (Ozempic)
- Semaglutide (Rybelsus)
- Side Effects and Monitoring
- Contraindications
- GIP/GLP-1 RAs
- Pharmacokinetics
- Dosing
- Side Effects
- Contraindications and Warnings
- Choice of Glucose-Lowering Therapy
- Type 2 Diabetes Mellitus
- Cardiovascular and Renal Protection
- Short-Acting vs. Long-Acting Agents
- Glycemic Control
- Weight Loss
- Combination Therapy
- Renal and Hepatic Disease
- Patient Counseling Points
- Administration
- Injection Technique
- Storage
- Summary
From April 3, 2026 through April 3, 2029, participants must:
- Read the "learning objectives" and "author and planning team disclosures"
- Study the section entitled "educational activity"
- Complete the Course Test and Evaluation form. The Course Test will be graded automatically. Following successful completion of the Course Test with a score of 70% or higher, a statement of participation will be made available immediately. (No partial credit will be given.)
Credit for this course will be automatically uploaded to CPE Monitor®.
Faculty Planner Disclosure
The following individuals were involved in planning, developing, and/or authoring this activity: L. Austin Fredrickson, MD, FACP; Liz Fredrickson, PharmD, BCPS; and Pamela Sardo, PharmD, BS. None of the individuals involved in developing this activity has a conflict of interest or financial relationships related to the subject matter. There are no financial relationships or commercial or financial support relevant to this activity to report or disclose by RxCe.com or any of the individuals involved in the development of this activity.
Unlabeled Use Disclosure
The information provided in this course is general in nature, and it is designed solely to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant's professional practice, including but not limited to patient assessment, diagnosis, treatment, and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice. Healthcare professionals must consult their employer, healthcare facility, hospital, or other organization for guidelines, protocols, and procedures to follow. The information provided in this course does not replace those guidelines, protocols, and procedures, but is for academic purposes only, and this course's limited purpose is for the completion of continuing education credits. Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses is constantly changing. Any person taking this course understands that such a person must make an independent review of medication information before any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only, and such uses are not endorsed hereby. Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course or course material.
Please ensure the device you plan to use meets these requirements:
- Operating System: Windows 7, 8, 10, or 11 / Mac OS X 10.9 or later / iOS / Android
- Supported Browsers: Microsoft Edge, Firefox, Google Chrome, Safari, Opera
- A connection to the internet
Accreditation
In support of improving patient care, RxCE.com is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PTCB Recognition
RxCe.com, LLC, offers pharmacy technician continuing education courses for PTCB recertification. Pharmacy technician courses are indicated both in the Target Audience description and the ACPE UAN which will end with a "T".